D. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)

Key Points

• Investment analysts at D. Boral Capital have reaffirmed their "buy" rating for OS Therapies (NYSE:OSTX) with a price objective of $20.00.
• The stock experienced a 5.8% increase, opening at $2.39 and demonstrating significant growth potential with a market cap of $75.63 million.
• Recent institutional investments include Bridgeway Capital Management and XTX Topco Ltd, indicating positive sentiment and confidence in the company's future prospects.

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $20.00 price target on the stock.

OS Therapies Stock Performance

NYSE OSTX traded up $0.11 on Tuesday, reaching $2.20. 389,796 shares of the stock traded hands, compared to its average volume of 735,060. The company has a fifty day moving average price of $1.92 and a 200-day moving average price of $1.75. The company has a market cap of $69.62 million and a price-to-earnings ratio of -2.78. OS Therapies has a 12 month low of $1.12 and a 12 month high of $7.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CM Management LLC increased its position in OS Therapies by 172.6% during the 1st quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after buying an additional 189,956 shares in the last quarter. XTX Topco Ltd acquired a new position in OS Therapies during the 2nd quarter valued at about $63,000. Finally, Bridgeway Capital Management LLC acquired a new position in OS Therapies during the 2nd quarter valued at about $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.